Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.49 |
| ▸ | HTR2C | P28335 | 9/20 | 0.49 |
| ▸ | HTR2B | P41595 | 7/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946677 | 0.92 | HTR2C (0.49) | HTR2AHTR2CHTR2B | |
| SCHEMBL4026931 | 0.91 | KDM4E (0.45) | HTR2AHTR2CMCHR1KDREPHA2 | |
| SCHEMBL13946856 | 0.91 | HTR2C (0.49) | HTR2AHTR2CHTR2BMCHR1KDR | |
| SCHEMBL6220699 | 0.88 | HTR2C (0.53) | HTR2AHTR2CMCHR1KDREPHA2 | |
| SCHEMBL13946461 | 0.86 | HTR2A (0.50) | HTR2AHTR2CHTR2BMCHR1KDR | |
| SCHEMBL13946676 | 0.86 | HTR2A (0.50) | HTR2AHTR2CHTR2BMCHR1KDR | |
| SCHEMBL13946457 | 0.86 | KDR (0.44) | HTR2AHTR2CMCHR1KDREPHA2 | |
| SCHEMBL6182880 | 0.83 | HSP90AA1 (0.40) | KDREPHA2EPHB4 | |
| SCHEMBL13945743 | 0.82 | HTR2C (0.48) | HTR2AHTR2CHTR2BMCHR1ADRA1A | |
| SCHEMBL13946678 | 0.81 | HTR2C (0.46) | HTR2AHTR2CMCHR1KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HTR2A 17/4885HTR2C 2/4885HTR2B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.